Treatment and Cost of Hepatocellular Carcinoma: A Population-Based Cohort Study in Taiwan

Abstract

Hepatitis B virus vaccination and antiviral therapies reduce the risk of hepatocellular carcinoma (HCC). However, the lifetime healthcare expenditure involved in caring for HCC patients remains unclear. We examined the use and direct costs of healthcare services for a cohort of HCC patients to the healthcare system using Taiwan national health insurance program research database between 1997 and 2012. Total medical cost for all reimbursed patient encounters, including hospitalizations and outpatient care was cumulated from HCC onset to the end of follow-up or death. The mean follow-up time was 2.7 years (standard deviation, SD = 3.3) for the entire HCC cohort. Insurance payments of approximately US$92 million were made to 5522 HCC patients, with a mean cost of US$16,711 per patient (21,350). On average, the total cost per patient per month was US$2143 (5184); it was 50% higher for advanced cirrhosis patients at the baseline but 23% lower for mild-to-moderate cirrhotic patients. In the two-part regression, patients’ underlying comorbid conditions, liver transplants, hepatectomy, and transarterial chemoembolization were associated with increased total cost, with liver transplants having the greatest impact over time. Hepatocellular carcinoma imposes substantial burden on the healthcare system. Real-world evidence on treatment and cost outcomes highlighted the needs to expand effective screening strategies and to optimize healthcare delivery to meet HCC patients’ clinical needs.

Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study

“…The cohort included 2209 (46.38%) HBV carriers, 812 (17.05%) HCV carriers, and 161 patients infected with both (3.38%). Second to virus infection status, liver cirrhosis (66.02%) was the most common medical condition, followed by diabetes mellitus (34.22%) 17 . Moreover, 1574 (66.41%) and 786 (80.78%) HCC patients had cirrhosis with underlying HBV and HCV, respectively.…”

Liver‐related long‐term outcomes of thiazolidinedione use in persons with type 2 diabetes

“…TZD can induce cell cycle arrest and apoptosis and inhibit cancer cell proliferation and invasion through the activation of PPARγ . Some studies have revealed that TZD use may decrease the risk of HCC in T2DM . However, another study provided contrasting results .…”

Current status, problems, and perspectives of non-alcoholic fatty liver disease research

“…A PPARγ activator, pioglitazone increases circulating adiponectin and attenuates insulin resistance, steatosis, lobular inflammation, and fibrosis in diabetic/pre-diabetic NASH patients (ClinicalTrials.gov Identifier: NCT00994682)[80]. PPARγ agonist might also reduce HCC prevalence in diabetic patients[81], but fluid retention (edema, heart failure) and osteoporosis were observed as major adverse effects[82]. For all pharmacological agents, the balance of long-term benefits and risks along with improvements to minimize adverse effects remain a constant challenge.…”